Should you buy Halozyme Therapeutics stock now?
Yes, the technical signal for Halozyme Therapeutics is currently BUY. Halozyme Therapeutics trades at $83.63 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 2.353 with rising momentum (signal: 2.283); RSI is at 67.0 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $86.89 points to 3.9% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Halozyme Therapeutics stock?
The average analyst price target for Halozyme Therapeutics is $86.89. The current price is $83.63, which gives an upside of 3.9%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $78.20 and $95.58.
Is Halozyme Therapeutics a dividend stock?
No, Halozyme Therapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Halozyme Therapeutics stock?
Halozyme Therapeutics is rated as a stock with moderately low risk. the annual standard deviation is 30.7%, which classifies the stock as moderately low risk.
Is Halozyme Therapeutics overvalued?
Halozyme Therapeutics is considered fairly valued – the price is close to the analyst price target. Halozyme Therapeutics has the following valuation ratios: a P/E ratio of 29.2 (moderately to highly valued), a P/S ratio of 6.5, a P/B ratio of 44.6. The stock trades close to the analyst price target and is considered fairly valued.
Is Halozyme Therapeutics overbought?
No, Halozyme Therapeutics is not overbought. RSI is at 67.0 (neutral zone). The technical indicators show: RSI is at 67.0 (upper neutral zone), which shows positive momentum but is not yet overbought. In addition, the price is 4.8% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Halozyme Therapeutics earnings report?
Halozyme Therapeutics reports earnings TODAY, August 6, 2026! The stock currently trades at $83.63. Watch how the price reacts after the release. With a P/E ratio of 29.2, the market will be watching closely whether earnings meet expectations. The RSI is at 67.0, so the report can reinforce the current technical trend.
Is Halozyme Therapeutics shorted?
Yes, Halozyme Therapeutics is shorted with 14.5% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying Halozyme Therapeutics stock?
No, insiders are not buying Halozyme Therapeutics shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 12 sales. On a net basis, 8,915,370 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 14,894,184 $ sold. Active sellers include Torley Helen, Connaughton Bernadette, RAMSAY DAVID A and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Halozyme Therapeutics a good stock?
Based on our total score, Halozyme Therapeutics is rated as a good stock with a total score of 68 out of 100. The stock scores above average on value, quality and momentum – it is among the top 32% in our database. The score is made up of Value: 28/100, Quality: 84/100, Momentum: 91/100. In addition: technical signal: Strong Buy. Whether Halozyme Therapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Halozyme Therapeutics stock?
The outlook for Halozyme Therapeutics based on current data: the average analyst price target is $86.89 (+3.9%); the stock is in an uptrend (above SMA50 and SMA200); the next earnings report is due on 8/6/2026, which can move the price; the P/E ratio is 29.2 (moderate). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Halozyme Therapeutics stock rising?
Halozyme Therapeutics is rising right now. The technical indicators show: the price is 4.8% above the 20-day average; MACD is positive with rising momentum (bullish signal); short interest is 14.5% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Halozyme Therapeutics go?
The average analyst price target for Halozyme Therapeutics is $86.89, which corresponds to a potential gain of 3.9% from the current price of $83.63. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Halozyme Therapeutics fall?
We lack enough history to give a specific floor for Halozyme Therapeutics. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Halozyme Therapeutics do?
Halozyme Therapeutics, Inc. driver en biotek-platform, der udvikler og sælger enzymer og medicinsk udstyr. De tjener især penge på deres patenterede rHuPH20-enzym, som gør det nemmere at give injektioner under huden.
Halozyme er kendt for produkter som Hylenex, der forbedrer ... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Halozyme Therapeutics as an investment.
Did Halozyme Therapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Halozyme Therapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Halozyme Therapeutics making money or losing money?
Yes, Halozyme Therapeutics is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 23.1% — which is excellent. The operating margin (profit before interest and taxes) is 49.0%. At a P/E ratio of 29.2, you currently pay 29.2 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Halozyme Therapeutics go bankrupt?
The bankruptcy risk of Halozyme Therapeutics is rated as low. Altman Z2 (a model for assessing financial distress) is 3.23 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 5 — which is average. Debt relative to equity is 467% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Halozyme Therapeutics have a lot of debt?
Yes, Halozyme Therapeutics has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 467%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Halozyme Therapeutics service its debt? Can service its debt without problems — the interest coverage ratio (how many times earnings can cover interest payments) is 33.7x, and net debt equals 1.9 years of earnings (EBITDA).
